ANTI-CHLAMYDIAL HSP60 CLONE A57-B9 (C005B-450540)

General description

Chlamydia trachomatis is a Gram-negative bacterium that is responsible to sexually transmitted diseases leading to pelvic inflammatory disease, ectopic pregnancy, infertility, and outbreaks of trachoma-associated blindness and lymphogranuloma venereum (LGV). Chlamydia trachomatis consists of eighteen different serological variants (serovars) that include a few subvariants. These are identified based on serological reactivity of the epitopes on their outer membrane. Intracellularly chlamydia replicates within a vacuole. Chlamydia infection is initiated with the expression of a chlamydial early gene product(s), which isolate the inclusion from the endocytic-lysosomal pathway and makes it fusogenic with sphingomyelin-containing exocytic vesicles. This change in vesicular interaction allows the delivery of the vacuole to the peri-Golgi region of the host cell. Antigens from all members of the Chlamydia genus display heat resistance and sensitivity to oxidation by sodium periodate. Clone A57-B9 detects Chlamydial HSP60 (GroEL). It reacts with the short peptide of 6 amino acids from the carboxyl terminal region of HSP60. HSP60 facilitates the correct folding of imported proteins and may prevent misfolding and promote the refolding and proper assembly of unfolded polypeptides generated under stress conditions.

Specificity

Clone A57-B9 detects Chlamydial HSP60. It targets an epitope with in 144 amino acids in the carboxy terminal of HSP60.

Immunogen

Recombinant Chlamydia trachomatis serovar A HSP60 emulsified in complete Freund adjuvant.

Application

Anti-Chlamydial HSP60, clone A57-B9, Cat. No. MABF2108, is a mouse monoclonal antibody that detects Chlamydial HSP60 and has been tested for use in ELISA, Immunofluorescence, Immunocytochemistry, and Western Blotting.

Immunocytochemistry Analysis: A representative lot detected Chlamydial HSP60 in Immunocytochemistry applications (Yuan, Y., et. al. (1992). Infect Immun. 60(6):2288-96).

Immunofluorescence Analysis: A representative lot detected Chlamydial HSP60 in Immunofluorescence applications (Southern, T., et. al. (2012). Clin Vaccine Immunol. 19(11):1864-9).

ELISA Analysis: A representative lot detected Chlamydial HSP60 in ELISA applications (Morrison, S.G., et. al. (2005). J Immunol. 175(11):7536-42).

Western Blotting Analysis: A representative lot detected chlamydial HSP60 in Western Blotting applications (Hechard, C., et. al. (2004). J Med Microbiol. 53(Pt 9):861-8; LaVerda, D., et. al. (1997). J Clin Microbiol. 35(5):1209-15; Southern, T., et. al. (2012). Clin Vaccine Immunol. 19(11):1864-9; Yuan, Y., et. al. (1992). Infect Immun. 60(6):2288-96).

Research Category
Inflammation & Immunology

Quality

Evaluated by Western Blotting in lysates from HeLa cells infected with chlamydia trachomatis serovar L2 (LGV 434 L2) .

Western Blotting Analysis: 2 µg/mL of this antibody detected Chlamydial HSP60 in lysates from HeLa cells infected with Chlamydia trachomatis serovar L2 (LGV 434 L2) .

Target description

~60 kDa observed. Uncharacterized bands may be observed in some lysate(s).

Physical form

Format: Purified

Protein G purified

Purified mouse monoclonal antibody IgG1 in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide.

Storage and Stability

Stable for 1 year at 2-8°C from date of receipt.

Other Notes

Concentration: Please refer to lot specific datasheet.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.